Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients
NCT ID: NCT03071016
Last Updated: 2019-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2000 participants
OBSERVATIONAL
2017-03-04
2018-03-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
NCT04445714
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
NCT05457933
Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors
NCT04304430
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
NCT02700334
Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity
NCT03313752
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who provide written informed consent.
3. Patients with previously diagnosed Type-2 diabetes mellitus
4. Patients with inadequately controlled diabetes (HbA1c \>7%) with existing anti-diabetic medications, prior to initiation of dapagliflozin treatment.
5. Patients who are taking dapagliflozin within last 3 months.
Exclusion Criteria
2. Patients with any medical condition which in the opinion of the investigator would interfere with safe completion of the study
3. Pregnant or lactating women
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Vijay Viswanathan, M.D., Ph.D., FRCP
Role: PRINCIPAL_INVESTIGATOR
MV Hospital Chennai India
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Hyderabad, Andhra Pradesh, India
Research Site
Nellor, Andhra Pradesh, India
Research Site
Vijayawada, Andhra Pradesh, India
Research Site
Raipur, Chhattisgarh, India
Research Site
Ahmedabad, Gujarat, India
Research Site
Rajkot, Gujarat, India
Research Site
Surat, Gujarat, India
Research Site
Bangalore, Karnataka, India
Research Site
Aurangabad, Maharashtra, India
Research Site
Mumbai, Maharashtra, India
Research Site
Nagpur, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
New Delhi, National Capital Territory of Delhi, India
Research Site
Amritsar, Punjab, India
Research Site
Bhathinda, Punjab, India
Research Site
Chandigarh, Punjab, India
Research Site
Ludhiana, Punjab, India
Research Site
Patiāla, Punjab, India
Research Site
Jaipur, Rajasthan, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Coimbatore, Tamil Nadu, India
Research Site
Madurai, Tamil Nadu, India
Research Site
Pudhucherry, Tamil Nadu, India
Research Site
Salem, Tamil Nadu, India
Research Site
Hyderabad, Telangana, India
Research Site
Kanpur, Uttar Pradesh, India
Research Site
Lucknow, Uttar Pradesh, India
Research Site
Jalpāiguri, West Bengal, India
Research Site
Kolkata, West Bengal, India
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1690R00029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.